Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06450106

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
18 (estimated)
Sponsor
SURGE Therapeutics · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Detailed description

A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Conditions

Interventions

TypeNameDescription
DRUGSTM-416pSTM-416p monotherapy

Timeline

Start date
2025-05-08
Primary completion
2026-09-01
Completion
2026-12-01
First posted
2024-06-10
Last updated
2026-02-19

Locations

4 sites across 2 countries: United States, Australia

Regulatory

Source: ClinicalTrials.gov record NCT06450106. Inclusion in this directory is not an endorsement.

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy (NCT06450106) · Clinical Trials Directory